Biogen Idec buys rights to MS pill
NEW YORK - Biogen Idec Inc., the world’s largest maker of drugs for multiple sclerosis, will pay as much as $510 million for rights to market Acorda Therapeutics Inc.’s experimental MS pill outside the United States. (Full article: 248 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
